Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation
Abstract: Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual disturbance. Conventional ophthalmic treatments present limitations such as low bioavailability and side e...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:2445/181470 |
| Acceso en línea: | https://hdl.handle.net/2445/181470 |
| Access Level: | acceso abierto |
| Palabra clave: | Síndromes de l'ull sec Oftalmopaties Sistemes d'alliberament de medicaments Agents antiinflamatoris Farmacologia ocular Dry eye syndromes Ophthalmopathies Drug delivery systems Antiinflammatory agents Ocular pharmacology |
| id |
ES_3a17fddaae2f4b1ec6dd43fced51c5b9 |
|---|---|
| oai_identifier_str |
oai:recercat.cat:2445/181470 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular InflammationLópez-Machado, AnaDíaz Garrido, NataliaCano Fernández, AmandaEspina García, MartaBadía Palacín, JosefaBaldomà Llavinés, LauraCalpena Campmany, Ana CristinaSouto, Eliana B.García López, María LuisaSánchez-López, E. (Elena)Síndromes de l'ull secOftalmopatiesSistemes d'alliberament de medicamentsAgents antiinflamatorisFarmacologia ocularDry eye syndromesOphthalmopathiesDrug delivery systemsAntiinflammatory agentsOcular pharmacologyAbstract: Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual disturbance. Conventional ophthalmic treatments present limitations such as low bioavailability and side effects. Lactoferrin (LF) constitutes a promising therapeutic tool, but its poor aqueous stability and high nasolacrimal duct drainage hinder its potential efficacy. In this study, we incorporate lactoferrin into hyaluronic acid coated liposomes by the lipid film method, followed by high pressure homogenization. Pharmacokinetic and pharmacodynamic profiles were evaluated in vitro and ex vivo. Cytotoxicity and ocular tolerance were assayed both in vitro and in vivo using New Zealand rabbits, as well as dry eye and anti-inflammatory treatments. LF loaded liposomes showed an average size of 90 nm, monomodal population, positive surface charge and a high molecular weight protein encapsulation of 53%. Biopharmaceutical behaviour was enhanced by the nanocarrier, and any cytotoxic effect was studied in human corneal epithelial cells. Developed liposomes revealed the ability to reverse dry eye symptoms and possess anti-inflammatory efficacy, without inducing ocular irritation. Hence, lactoferrin loaded liposomes could offer an innovative nanotechnological tool as suitable approach in the treatment of DED.MDPI2021202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/181470Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics13101698Pharmaceutics, 2021, vol. 13, num. 10, p. 1698https://doi.org/10.3390/pharmaceutics13101698cc-by (c) López-Machado, Ana et al., 2021https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1814702026-05-29T05:05:01Z |
| dc.title.none.fl_str_mv |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation |
| title |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation |
| spellingShingle |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation López-Machado, Ana Síndromes de l'ull sec Oftalmopaties Sistemes d'alliberament de medicaments Agents antiinflamatoris Farmacologia ocular Dry eye syndromes Ophthalmopathies Drug delivery systems Antiinflammatory agents Ocular pharmacology |
| title_short |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation |
| title_full |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation |
| title_fullStr |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation |
| title_full_unstemmed |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation |
| title_sort |
Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation |
| dc.creator.none.fl_str_mv |
López-Machado, Ana Díaz Garrido, Natalia Cano Fernández, Amanda Espina García, Marta Badía Palacín, Josefa Baldomà Llavinés, Laura Calpena Campmany, Ana Cristina Souto, Eliana B. García López, María Luisa Sánchez-López, E. (Elena) |
| author |
López-Machado, Ana |
| author_facet |
López-Machado, Ana Díaz Garrido, Natalia Cano Fernández, Amanda Espina García, Marta Badía Palacín, Josefa Baldomà Llavinés, Laura Calpena Campmany, Ana Cristina Souto, Eliana B. García López, María Luisa Sánchez-López, E. (Elena) |
| author_role |
author |
| author2 |
Díaz Garrido, Natalia Cano Fernández, Amanda Espina García, Marta Badía Palacín, Josefa Baldomà Llavinés, Laura Calpena Campmany, Ana Cristina Souto, Eliana B. García López, María Luisa Sánchez-López, E. (Elena) |
| author2_role |
author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Síndromes de l'ull sec Oftalmopaties Sistemes d'alliberament de medicaments Agents antiinflamatoris Farmacologia ocular Dry eye syndromes Ophthalmopathies Drug delivery systems Antiinflammatory agents Ocular pharmacology |
| topic |
Síndromes de l'ull sec Oftalmopaties Sistemes d'alliberament de medicaments Agents antiinflamatoris Farmacologia ocular Dry eye syndromes Ophthalmopathies Drug delivery systems Antiinflammatory agents Ocular pharmacology |
| description |
Abstract: Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual disturbance. Conventional ophthalmic treatments present limitations such as low bioavailability and side effects. Lactoferrin (LF) constitutes a promising therapeutic tool, but its poor aqueous stability and high nasolacrimal duct drainage hinder its potential efficacy. In this study, we incorporate lactoferrin into hyaluronic acid coated liposomes by the lipid film method, followed by high pressure homogenization. Pharmacokinetic and pharmacodynamic profiles were evaluated in vitro and ex vivo. Cytotoxicity and ocular tolerance were assayed both in vitro and in vivo using New Zealand rabbits, as well as dry eye and anti-inflammatory treatments. LF loaded liposomes showed an average size of 90 nm, monomodal population, positive surface charge and a high molecular weight protein encapsulation of 53%. Biopharmaceutical behaviour was enhanced by the nanocarrier, and any cytotoxic effect was studied in human corneal epithelial cells. Developed liposomes revealed the ability to reverse dry eye symptoms and possess anti-inflammatory efficacy, without inducing ocular irritation. Hence, lactoferrin loaded liposomes could offer an innovative nanotechnological tool as suitable approach in the treatment of DED. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 2021 2021 2021 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/2445/181470 |
| url |
https://hdl.handle.net/2445/181470 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics13101698 Pharmaceutics, 2021, vol. 13, num. 10, p. 1698 https://doi.org/10.3390/pharmaceutics13101698 |
| dc.rights.none.fl_str_mv |
cc-by (c) López-Machado, Ana et al., 2021 https://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
cc-by (c) López-Machado, Ana et al., 2021 https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869406213287968768 |
| score |
15,812429 |